Anal cancer is of growing concern in the United States and elsewhere, particularly among HIV-positive men who have a much higher than normal incidence of this human papillomavirus-associated neoplasia. Standard of care chemoradiotherapy has remained unchanged for decades and is of limited value in treating patients with advanced or recurrent disease. Anal cancer is a poorly understood disease owing to the absence of preclinical models for its study. We have developed the first preclinical animal models for anal cancer. Using these models, we have begun to study the role of viral oncogenes in this cancer. Furthermore, we discovered that the mTOR pathway is highly activated in anal cancer and is a valuable target for treating this cancer. In this grant applicatin we propose experiments using these new preclinical models to understand the role and temporal requirements for individual HPV oncogenes in anal carcinogenesis, and their influences on the responses of anal cancer to chemoradiation. We will also carry out studies to investigate further the value of drugs targeting the mTOR and MEK/ERK pathways in treating anal cancer. Lastly we will investigate if PI3K activation, which is upstream of the MTOR and MEK/ERK pathways, drives anal carcinogenesis together with HPV oncogenes. The studies described in this grant will provide new insights into more effective ways for treating human anal cancer.
Anal Cancer is of growing significance particularly amongst HIV-infected individuals who are at greater than 50 times the risk of developing this cancer compared to the general population. Patients with metastatic or recurrent anal cancers have poor prognoses. We propose studies to define new therapeutic targets for treating anal cancer using our first-of-their-kind preclinical models for this debilitating disease.
|Shin, Myeong-Kyun; Payne, Susan N; Bilger, Andrea et al. (2018) Activating Mutations in Pik3caContribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes. Clin Cancer Res :|
|Carchman, Evie H; Matkowskyj, Kristina A; Meske, Louise et al. (2016) Dysregulation of Autophagy Contributes to Anal Carcinogenesis. PLoS One 11:e0164273|
|Nawandar, Dhananjay M; Wang, Anqi; Makielski, Kathleen et al. (2015) Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells. PLoS Pathog 11:e1005195|
|Wille, Coral K; Nawandar, Dhananjay M; Henning, Amanda N et al. (2015) 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch. Proc Natl Acad Sci U S A 112:E7257-65|
|Stein, Andrew P; Saha, Sandeep; Kraninger, Jennifer L et al. (2015) Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. Cancer J 21:138-46|
|Stein, Andrew P; Swick, Adam D; Smith, Molly A et al. (2015) Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Med 4:699-712|
|Spurgeon, Megan E; Cheng, Jingwei; Bronson, Roderick T et al. (2015) Tumorigenic activity of merkel cell polyomavirus T antigens expressed in the stratified epithelium of mice. Cancer Res 75:1068-79|
|den Boon, Johan A; Pyeon, Dohun; Wang, Sophia S et al. (2015) Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A 112:E3255-64|
|Warren, Cody J; Xu, Tao; Guo, Kejun et al. (2015) APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89:688-702|
|Vieira, Valdimara C; Leonard, Brandon; White, Elizabeth A et al. (2014) Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 5:|
Showing the most recent 10 out of 11 publications